The relationship among perceived stress, symptoms, and inflammation in persons with inflammatory bowel disease

American Journal of Gastroenterology

Volumn 110, Issue 7, 2015, Pages 1001-1012

  Targownik, Laura E ^a   Sexton, Kathryn A ^a   Bernstein, Matthew T ^a   Beatie, Brooke ^a   Sargent, Michael ^a   Walker, John R ^a   Graff, Lesley A ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CALGRANULIN;

ABDOMINAL PAIN; ADULT; ALCOHOL CONSUMPTION; ANOREXIA; ANUS FISSURE; APHTHOUS STOMATITIS; ARTHRALGIA; ARTICLE; CROHN DISEASE; CROHN DISEASE ACTIVITY INDEX; CROSS-SECTIONAL STUDY; DIGESTIVE SYSTEM INFLAMMATION; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE DURATION; DISEASE SEVERITY; ENTERITIS; ERYTHEMA NODOSUM; FECES ANALYSIS; FEMALE; HARVEY BRADSHAW INDEX; HUMAN; HUMAN TISSUE; INFLAMMATORY BOWEL DISEASE; LIQUID FECES; MAJOR CLINICAL STUDY; MALE; MANITOBA INFLAMMATORY BOWEL DISEASE INDEX; NAUSEA; PERCEIVED STRESS SCALE; POWELL TUCK INDEX; PREDICTIVE VALUE; PRIORITY JOURNAL; PYODERMA GANGRENOSUM; SENSITIVITY AND SPECIFICITY; STRESS; ULCERATIVE COLITIS; UVEITIS; AGED; CANADA; CHEMISTRY; COMPLICATION; EPIDEMIOLOGY; FECES; INFLAMMATION; INFLAMMATORY BOWEL DISEASES; MENTAL STRESS; METABOLISM; MIDDLE AGED; PERCEPTION; PSYCHOLOGY; QUESTIONNAIRE; REGISTER; SELF REPORT; SEVERITY OF ILLNESS INDEX; STATISTICAL MODEL;

ADULT; AGED; COLITIS, ULCERATIVE; CROHN DISEASE; CROSS-SECTIONAL STUDIES; FECES; FEMALE; HUMANS; INFLAMMATION; INFLAMMATORY BOWEL DISEASES; LEUKOCYTE L1 ANTIGEN COMPLEX; LOGISTIC MODELS; MALE; MANITOBA; MIDDLE AGED; QUESTIONNAIRES; REGISTRIES; SELF REPORT; SEVERITY OF ILLNESS INDEX; SOCIAL PERCEPTION; STRESS, PSYCHOLOGICAL;

EID: 84936846060     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2015.147     Document Type: Article

References (52)

1. Sandborn WJ. Mucosal healing with infliximab: results from the active ulcerative colitis trials. Gastroenterol Hepatol 2012; 8: 117-9.
2. Neurath MF, Travis SP. Mucosal healing in inflammatory bowel diseases: a systematic review. Gut 2012; 61: 1619-35.
3. Froslie KF, Jahnsen J, Moum BA, et al. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology 2007; 133: 412-22.
4. Colombel JF, Rutgeerts P, Reinisch W, et al. Early mucosal healing with infliximab is associated with improved long-Term clinical outcomes in ulcerative colitis. Gastroenterology 2011; 141: 1194-201.
5. Keohane J, O'Mahony C, O'Mahony L, et al. Irritable bowel syndrome-Type symptoms in patients with inflammatory bowel disease: a real association or refl ection of occult inflammation?. Am J Gastroenterol 2010; 105: 1788-89-94; quiz 95.
6. Halpin SJ, Ford AC. Prevalence of symptoms meeting criteria for irritable bowel syndrome in inflammatory bowel disease: systematic review and meta-Analysis. Am J Gastroenterol 2012; 107: 1474-82.
7. Berrill JW, Green JT, Hood K, et al. Symptoms of irritable bowel syndrome in patients with inflammatory bowel disease: examining the role of subclinical inflammation and the impact on clinical assessment of disease activity. Aliment Pharmacol Ther 2013; 38: 44-51.
8. Bernstein CN, Singh S, GraffLA, et al. A prospective population-based study of triggers of symptomatic fl ares in IBD. Am J Gastroenterol 2010; 105: 1994-2002.
9. Langhorst J, Hofstetter A, Wolfe F, et al. Short-Term stress, but not mucosal healing nor depression was predictive for the risk of relapse in patients with ulcerative colitis: a prospective 12-month follow-up study. inflamm Bowel Dis 2013; 19: 2380-6.
10. Bitton A, Sewitch MJ, Peppercorn MA, et al. Psychosocial determinants of relapse in ulcerative colitis: a longitudinal study. Am J Gastroenterol 2003; 98: 2203-8.
11. Singh S, GraffLA, Bernstein CN. Do NSAIDs, antibiotics, infections, or stress trigger fl ares in IBD?. Am J Gastroenterol 2009; 104: 1298-313. quiz 314.
12. Daperno M, D'Haens G, Van Assche G, et al. Development and validation of a new, simplifi ed endoscopic activity score for Crohn's disease: the SES-CD. Gastrointest Endosc 2004; 60: 505-12.
13. Vermeire S, Van Assche G, Rutgeerts P. Laboratory markers in IBD: useful, magic, or unnecessary toys?. Gut 2006; 55: 426-31.
14. Vermeire S, Van Assche G, Rutgeerts P. C-reactive protein as a marker for inflammatory bowel disease. inflamm Bowel Dis 2004; 10: 661-5.
15. Schoepfer AM, Vavricka S, Zahnd-Straumann N, et al. Monitoring inflammatory bowel disease activity: clinical activity is judged to be more relevant than endoscopic severity or biomarkers. Journal Crohns Colitis 2012; 6: 412-8.
16. Herrinton LJ, Liu L, Weng X, et al. Role of thiopurine and anti-TNF therapy in lymphoma in inflammatory bowel disease. Am J Gastroenterol 2011; 106: 2146-53.
17. Ricanek P, Brackmann S, Perminow G, et al. Evaluation of disease activity in IBD at the time of diagnosis by the use of clinical, biochemical, and fecal markers. Scand J Gastroenterol 2011; 46: 1081-91.
18. Schoepfer AM, Trummler M, Seeholzer P, et al. Discriminating IBD from IBS: comparison of the test performance of fecal markers, blood leukocytes, CRP, and IBD antibodies. inflamm Bowel Dis 2008; 14: 32-9.
19. Schoepfer AM, Beglinger C, Straumann A, et al. Fecal calprotectin correlates more closely with the Simple Endoscopic Score for Crohn's disease (SES-CD) than CRP, blood leukocytes, and the CDAI. Am J Gastroenterol 2010; 105: 162-9.
20. Bernstein CN, Rawsthorne P, Cheang M, et al. A population-based case control study of potential risk factors for IBD. Am J Gastroenterol 2006; 101: 993-1002.
21. Longobardi T, Walker JR, GraffLA, et al. Health service utilization in IBD: comparison of self-report and administrative data. BMC Health Serv Res 2011; 11: 137.
22. Lin JF, Chen JM, Zuo JH, et al. Meta-Analysis: fecal calprotectin for assessment of inflammatory bowel disease activity. inflamm Bowel Dis 2014; 20: 1407-15.
23. Meuwis MA, Vernier-Massouille G, Grimaud JC, et al. Serum calprotectin as a biomarker for Crohn's disease. J Crohns Colitis 2013; 7: e678-e683.
24. Harvey RF, Bradshaw JM. A simple index of Crohn's-disease activity. Lancet 1980; 1: 514.
25. Powell-Tuck J, Bown RL, Lennard-Jones JE. A comparison of oral prednisolone given as single or multiple daily doses for active proctocolitis. Scand J Gastroenterol 1978; 13: 833-7.
26. Turner D, Seow CH, Greenberg GR, et al. A systematic prospective comparison of noninvasive disease activity indices in ulcerative colitis. Clin Gastroenterol Hepatol 2009; 7: 1081-8.
27. Vermeire S, Schreiber S, Sandborn WJ, et al. Correlation between the Crohn's disease activity and Harvey-Bradshaw indices in assessing Crohn's disease severity. Clin Gastroenterol Hepatol 2010; 8: 357-63.
28. Sexton K, Targownik LE, Walker JR, et al. Development of an IBD symptom self-report scale for research and clinical application. Gastroenterology 2014; 146; 5(Supp1); S228-9.
29. Clara I, Lix LM, Walker JR, et al. The Manitoba IBD Index: evidence for a new and simple indicator of IBD activity. Am J Gastroenterol 2009; 104: 1754-63.
30. Cohen S, Kamarck T, Mermelstein R. A global measure of perceived stress. J Health Soc Behav 1983; 24: 385-96.
31. Cohen S, Doyle WJ, Skoner DP. Psychological stress, cytokine production, and severity of upper respiratory illness. Psychosom Med 1999; 61: 175-80.
32. Cohen S, Tyrrell DA, Smith AP. Psychological stress and susceptibility to the common cold. N Engl J Med 1991; 325: 606-12.
33. GraffLA, Walker JR, Lix L, et al. The relationship of inflammatory bowel disease type and activity to psychological functioning and quality of life. Clin Gastroenterol Hepatol 2006; 4: 1491-501.
34. D'Inca R, Dal Pont E, Di Leo V, et al. Can calprotectin predict relapse risk in inflammatory bowel disease?. Am J Gastroenterol 2008; 103: 2007-14.
35. van Rheenen PF, Van de Vijver E, Fidler V. Faecal calprotectin for screening of patients with suspected inflammatory bowel disease: diagnostic metaanalysis. BMJ 2010; 341: c3369.
36. Lobaton T, Lopez-Garcia A, Rodriguez-Moranta F, et al. A new rapid test for fecal calprotectin predicts endoscopic remission and postoperative recurrence in Crohn's disease. J Crohns Colitis 2013; 7: e641-51.
37. Lamb CA, Mohiuddin MK, Gicquel J, et al. Faecal calprotectin or lactoferrin can identify postoperative recurrence in Crohn's disease. Br J Surg 2009; 96: 663-74.
38. Farrokhyar F, Marshall JK, Easterbrook B, et al. Functional gastrointestinal disorders and mood disorders in patients with inactive inflammatory bowel disease: prevalence and impact on health. inflamm Bowel Dis 2006; 12: 38-46.
39. Duffy LC, Zielezny MA, Marshall JR, et al. Lag time between stress events and risk of recurrent episodes of inflammatory bowel disease. Epidemiology 1991; 2: 141-5.
40. Drossman DA, McKee DC, Sandler RS, et al. Psychosocial factors in the irritable bowel syndrome. A multivariate study of patients and nonpatients with irritable bowel syndrome. Gastroenterology 1988; 95: 701-8.
41. Drossman DA. Do psychosocial factors defi ne symptom severity and patient status in irritable bowel syndrome?. Am J Med 1999; 107: S41-50.
42. Koloski NA, Talley NJ, Boyce PM. Predictors of health care seeking for irritable bowel syndrome and nonulcer dyspepsia: a critical review of the literature on symptom and psychosocial factors. Am J Gastroenterol 2001; 96: 1340-9.
43. Whitehead WE, Crowell MD, Robinson JC, et al. Effects of stressful life events on bowel symptoms: subjects with irritable bowel syndrome compared with subjects without bowel dysfunction. Gut 1992; 33: 825-30.
44. Simren M, Axelsson J, Gillberg R, et al. Quality of life in inflammatory bowel disease in remission: the impact of IBS-like symptoms and associated psychological factors. Am J Gastroenterol 2002; 97: 389-96.
45. Minderhoud IM, Oldenburg B, Wismeijer JA, et al. IBS-like symptoms in patients with inflammatory bowel disease in remission; relationships with quality of life and coping behavior. Dig Dis Sci 2004; 49: 469-74.
46. Mikocka-Walus AA, Turnbull DA, Andrews JM, et al. The effect of functional gastrointestinal disorders on psychological comorbidity and quality of life in patients with inflammatory bowel disease. Aliment Pharmacol Th er 2008; 28: 475-83.
47. Caso JR, Leza JC, Menchen L. The effects of physical and psychological stress on the gastro-intestinal tract: lessons from animal models. Curr Mol Med 2008; 8: 299-312.
48. Mawdsley JE, Macey MG, Feakins RM, et al. The effect of acute psychologic stress on systemic and rectal mucosal measures of inflammation in ulcerative colitis. Gastroenterology 2006; 131: 410-9.
49. Keefer L, Keshavarzian A, Mutlu E. Reconsidering the methodology of "stress" research in inflammatory bowel disease. J Crohns Colitis 2008; 2: 193-201.
50. Mawdsley JE, Rampton DS. Psychological stress in IBD: new insights into pathogenic and therapeutic implications. Gut 2005; 54: 1481-91.
51. Levenstein S, Prantera C, Varvo V, et al. Stress and exacerbation in ulcerative colitis: a prospective study of patients enrolled in remission. Am J Gastroenterol 2000; 95: 1213-20.
52. Melesse DY TL, Singh H, Nugent Z, et al. Patterns of drug avoidance in patients with inflammatory bowel disease. Gastroenterology 2013; 144: S48-49.